MONTEVIDEO, Uruguay, Aug. 14, 2018 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 2Q18.
Gross revenues for 2Q18 grew 33% in constant currency, marking BRL 981M LTM.
Net revenues for 2Q18 increased by 42% in constant currency, marking BRL 882M LTM.
Gross profit up 39% in 2Q18, in constant currency. Gross margin of 53% in line with prior quarters.
Adjusted EBITDA increased by 65% in constant currency vs. 2Q17. Adjusted EBITDA margin came to 25% in 2Q18, improving 381 bps vs. 2Q17, marking BRL 226M LTM compared to BRL 203M in 2Q17 LTM.
Net income totaled BRL 20M in 2Q18, from a loss of BRL 3M in 2Q17. Adjusted net income up 380% from 2Q17, reaching BRL 32M in 2Q18.
Lenvima launching ahead of schedule and improving clinical profile with new indications submitted. Cresemba and Zevtera approved in Peru.
Extended partnership with Gilead into the Andean region, with revenues stream in 2Q18.
SOURCE Grupo Biotoscana